1-[2-(3-硝基-苯基)-乙基]-咪唑烷-2,4,5-三酮 | 1026925-68-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 1-[2-(3-硝基-苯基)-乙基]-咪唑烷-2,4,5-三酮
• 英文名称: 1-[2-(3-Nitrophenyl)ethyl]imidazolidine-2,4,5-trione
• CAS: 1026925-68-7
• 化学式: C₁₁H₉N₃O₅
• 分子量: 263.21
• InChiKey: ABDJBDNXDVGEJZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  19
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  112
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  1-[2-(3-硝基-苯基)-乙基]-咪唑烷-2,4,5-三酮 在 盐酸 、 氢氧化钾 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 12.5h， 生成 3-Carboxymethyl-1-(2-(3-nitrophenyl)ethyl)parabanic acid
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393
• 作为产物：
  描述：

  3-硝基苯乙胺 盐酸盐 在 盐酸 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 6.0h， 生成 1-[2-(3-硝基-苯基)-乙基]-咪唑烷-2,4,5-三酮
  参考文献：
  名称：

  Highly Selective Aldose Reductase Inhibitors. 1. 3-(Arylalkyl)-2,4,5-trioxoimidazolidine-1-acetic Acids

  摘要：

  A series of 3-(arylalkyl)-2,4,5-trioxoimidazolidine-1-acids (1) was prepared and tested for aldose reductase (AR) and aldehyde reductase (ALR) inhibitory activities. These compounds showed strong inhibitory activity against AR without significant inhibitory activity for ALR. The ratio of IC50(ALR)/IC50(AR) was > 1000 in some compouds. On the basis of pharmacological tests such as the recovery of reduced motor nerve conduction velocity and toxicological profile, 3-(3-nitrobenzyl)-2,4,5-trioxoimidazolidine-1-acid (NZ-314) was selected as the candidate for clinical development.

  DOI：

  10.1021/jm9508393